| NCT06989840 | Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne | RECRUITING | PHASE1 | 2025-05-19 | 2026-01-01 | 2025-12-01 |
| NCT06594523 | A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis | WITHDRAWN | PHASE3 | 2025-03 | 2030-12 | 2030-12 |
| NCT06692283 | A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH | WITHDRAWN | PHASE3 | 2025-03 | 2027-06 | 2026-06 |
| NCT05835180 | A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function | COMPLETED | PHASE1 | 2023-05-01 | 2023-12-18 | 2023-12-18 |
| NCT05657834 | Open-label Study of the Absorption, Metabolism, and Excretion of [14C]TVB-2640 Following a Single Oral Dose in Healthy Male Subjects | COMPLETED | PHASE1 | 2022-11-21 | 2022-12-21 | 2022-12-21 |
| NCT04906421 | Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH) | COMPLETED | PHASE2 | 2021-08-12 | 2023-10-02 | 2023-10-02 |
| NCT03938246 | Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | PHASE2 | 2019-03-22 | 2021-10-02 | 2021-10-02 |
| NCT02223247 | A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors | COMPLETED | PHASE1 | 2013-11 | 2017-06 | 2017-06 |